Ilaria Gareri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ilaria Gareri has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
- Angela Sciacqua
Department of Medical and Surgical Sciences, University “Magna Graecia” of Catanzaro, 88100 Catanzaro, Italy
3 shared publications - Caterina Palleria
Unit of Clinical Pharmacology and Pharmacovigilance, "Renato Dulbecco" University Hospital, Research Center FAS@UMG, Department of Health Science, Magna Graecia University, 88100, Catanzaro, Italy
3 shared publications - Giandomenico Severini
Department of Medical and Surgical Sciences, University Magna Graecia of Catanzaro, 88100 Catanzaro, Italy
3 shared publications - Giovambattista De Sarro
Department of Health Sciences, University “Magna Graecia” of Catanzaro, 88100 Catanzaro, Italy
3 shared publications - Giuseppe Armentaro
Department of Medical and Surgical Sciences University Magna Græcia of Catanzaro Catanzaro Italy
3 shared publications - Luca Gallelli
Department of Health Sciences, Magna Graecia University of Catanzaro, 88100 Catanzaro, Italy
3 shared publications
Latest Publications
- Open Access
- 8 June 2026
- Published by Springer Nature in Aging Clinical and Experimental Research
- Vol. 38 (1)
“The sound of silence”: when the brain doesn’t hear
Cognitive impairment is one of the leading causes of disability worldwide and it affects about 6.5% of the population over the age of 65. Hearing impairment is a significant health problem and a possible cause for dementia. Preventing hearing loss or at least correcting it by the use of acoustic prosthesis may reduce the onset of dementia in old age. Indeed, hearing loss has been proposed as a risk factor for dementia, even if the mechanisms that correlate the two diseases are not yet fully understood. It can accelerate existing mild cognitive impairment by increasing the cognitive burden and/or exhausting existing cognitive compensatory strategies, and it could also increase social isolation. Peripheral hearing impairments and Central Auditory Processing (CAP) dysfunction should both be evaluated. Indeed, although peripheral auditory function impairment is perhaps the primary pathological component of early age-related hearing loss (ARHL), CAP dysfunction becomes increasingly important in the later stages of ARHL. The assessment of peripheral hearing function includes self-reporting and some screening tests (such as the 10-item Hearing Handicap Inventory for the Elderly - Short Form), a first-level clinical assessment for hearing loss (such as spoken voice or finger friction tests), audiometric screening tests (portable audiometers, portable audio) and diagnostic audiometric tests (such as pure tone audiometry in a soundproof booth to test the acoustic threshold). The present article focuses on the possible connection between sensory deprivation and the development of cognitive impairment in late age. The use of hearing aids and cognitive training could help delay or prevent the onset of cognitive decline. Furthermore, the use of hearing aids can be an effective tool not only to minimize perceived disability in older individuals, but also to reduce the caregiver’s burden by improving the patients’ ability to communicate.
- 8 June 2026
- Published by Springer Nature in Aging Clinical and Experimental Research
- Vol. 38 (1)
Open Access“The sound of silence”: when the brain doesn’t hear
Cognitive impairment is one of the leading causes of disability worldwide and it affects about 6.5% of the population over the age of 65. Hearing impairment is a significant health problem and a possible cause for dementia. Preventing hearing loss or at least correcting it by the use of acoustic prosthesis may reduce the onset of dementia in old age. Indeed, hearing loss has been proposed as a risk factor for dementia, even if the mechanisms that correlate the two diseases are not yet fully understood. It can accelerate existing mild cognitive impairment by increasing the cognitive burden and/or exhausting existing cognitive compensatory strategies, and it could also increase social isolation. Peripheral hearing impairments and Central Auditory Processing (CAP) dysfunction should both be evaluated. Indeed, although peripheral auditory function impairment is perhaps the primary pathological component of early age-related hearing loss (ARHL), CAP dysfunction becomes increasingly important in the later stages of ARHL. The assessment of peripheral hearing function includes self-reporting and some screening tests (such as the 10-item Hearing Handicap Inventory for the Elderly - Short Form), a first-level clinical assessment for hearing loss (such as spoken voice or finger friction tests), audiometric screening tests (portable audiometers, portable audio) and diagnostic audiometric tests (such as pure tone audiometry in a soundproof booth to test the acoustic threshold). The present article focuses on the possible connection between sensory deprivation and the development of cognitive impairment in late age. The use of hearing aids and cognitive training could help delay or prevent the onset of cognitive decline. Furthermore, the use of hearing aids can be an effective tool not only to minimize perceived disability in older individuals, but also to reduce the caregiver’s burden by improving the patients’ ability to communicate.
- Open Access
- 4 June 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (6) , 1282
Reply to Yavuz, S. Comment on “Martire et al. Prognostic Role of High-Sensitivity C-Reactive Protein/Albumin Ratio in Heart Failure Patients. Biomedicines 2026, 14, 748”
We would like to thank the author for the careful evaluation of our manuscript and for the thoughtful comments
- 4 June 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (6) , 1282
Open AccessReply to Yavuz, S. Comment on “Martire et al. Prognostic Role of High-Sensitivity C-Reactive Protein/Albumin Ratio in Heart Failure Patients. Biomedicines 2026, 14, 748”
We would like to thank the author for the careful evaluation of our manuscript and for the thoughtful comments
- Open Access
- 24 May 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (6) , 1187
Phenotyping of Obstructive Sleep Apnea Syndrome and Association with Cognitive Impairment, a Real-Life Study
Introduction: Obstructive sleep apnea (OSA) is highly prevalent, affecting up to 50% of individuals over 65 years. Elderly patients often present with atypical, fewer and less severe symptoms, suggesting age-specific phenotypes. However, comprehensive clinical phenotyping that incorporates cognitive outcomes remains limited. This study aimed to characterize OSA phenotypes through cluster analysis and evaluate their association with cognitive impairment, independently of age. Materials and Methods: Between 2020 and 2024, 409 adults with moderate-to-severe OSA were enrolled and stratified into three age groups (p < 0.001), despite comparable polysomnographic severity across age groups. Cluster analysis identified three phenotypes: Cluster 1 (classical OSA: high AHI, BMI, T90, ESS); Cluster 2 (geriatric phenotype: low AHI, BMI, T90, ESS, highest cognitive impairment rate: 27.7%); Cluster 3 (hypersymptomatic: low AHI and T90, high sleepiness and asthenia, prevalent depression). On multivariate regression, age (OR 1.155; p < 0.001), male sex (OR 2.223; p = 0.034), and Cluster 2 (OR 3.131; p < 0.001) were independent predictors of cognitive impairment. Conclusions: Three clinically distinct OSA phenotypes were identified regardless of age and severity. The geriatric phenotype was associated with three-fold increased risk of cognitive impairment, supporting routine cognitive screening and age-adapted diagnostic strategies in elderly OSA patients.
- 24 May 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (6) , 1187
Open AccessPhenotyping of Obstructive Sleep Apnea Syndrome and Association with Cognitive Impairment, a Real-Life Study
Introduction: Obstructive sleep apnea (OSA) is highly prevalent, affecting up to 50% of individuals over 65 years. Elderly patients often present with atypical, fewer and less severe symptoms, suggesting age-specific phenotypes. However, comprehensive clinical phenotyping that incorporates cognitive outcomes remains limited. This study aimed to characterize OSA phenotypes through cluster analysis and evaluate their association with cognitive impairment, independently of age. Materials and Methods: Between 2020 and 2024, 409 adults with moderate-to-severe OSA were enrolled and stratified into three age groups (p < 0.001), despite comparable polysomnographic severity across age groups. Cluster analysis identified three phenotypes: Cluster 1 (classical OSA: high AHI, BMI, T90, ESS); Cluster 2 (geriatric phenotype: low AHI, BMI, T90, ESS, highest cognitive impairment rate: 27.7%); Cluster 3 (hypersymptomatic: low AHI and T90, high sleepiness and asthenia, prevalent depression). On multivariate regression, age (OR 1.155; p < 0.001), male sex (OR 2.223; p = 0.034), and Cluster 2 (OR 3.131; p < 0.001) were independent predictors of cognitive impairment. Conclusions: Three clinically distinct OSA phenotypes were identified regardless of age and severity. The geriatric phenotype was associated with three-fold increased risk of cognitive impairment, supporting routine cognitive screening and age-adapted diagnostic strategies in elderly OSA patients.
- Open Access
- 25 March 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (4) , 748
Prognostic Role of High-Sensitivity C-Reactive Protein/Albumin Ratio in Heart Failure Patients
The ratio of high-sensitivity C-reactive protein (hs-CRP) to Serum albumin (SA) (hs-CRP/SA) is emerging as a new potential biomarker capable of stratifying cardiovascular risk in patients with chronic HF (CHF), particularly the risk of major adverse cardiovascular events (MACEs). Objectives: The aim of this study was to evaluate the long-term prognostic value of the hs-CRP/SA ratio on the risk of MACEs in a population of outpatients with CHF. Methods: In this retrospective observational study, 500 patients were enrolled and were stratified into two groups based on the median value of the hs-CRP/SA ratio: 249 patients with hs-CRP/SA < 1.19 and 251 patients with hs-CRP/SA ≥ 1.19. Results: During median follow-up of 5.2 years, 3.6 MACEs/100 patients/year were detected; patients with hs-CRP/SA ≥ 1.19 had a MACE incidence of 5.9 events per 100 patient-years, compared with 1.2 events per 100 patient-years in those with hs-CRP/AS < 1.19 (p < 0.001). Multivariate analysis confirmed that hs-CRP/SA ≥ 1.19 was associated with an approximately 6.5-fold increased risk of new MACEs (HR 6.513, 95% CI 3.928–10.797; p < 0.001). Conclusions: The hs-CRP/SA ratio is confirmed as a powerful prognostic marker in patients with CHF, associated with a significantly increased risk of MACEs.
- 25 March 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (4) , 748
Open AccessPrognostic Role of High-Sensitivity C-Reactive Protein/Albumin Ratio in Heart Failure Patients
The ratio of high-sensitivity C-reactive protein (hs-CRP) to Serum albumin (SA) (hs-CRP/SA) is emerging as a new potential biomarker capable of stratifying cardiovascular risk in patients with chronic HF (CHF), particularly the risk of major adverse cardiovascular events (MACEs). Objectives: The aim of this study was to evaluate the long-term prognostic value of the hs-CRP/SA ratio on the risk of MACEs in a population of outpatients with CHF. Methods: In this retrospective observational study, 500 patients were enrolled and were stratified into two groups based on the median value of the hs-CRP/SA ratio: 249 patients with hs-CRP/SA < 1.19 and 251 patients with hs-CRP/SA ≥ 1.19. Results: During median follow-up of 5.2 years, 3.6 MACEs/100 patients/year were detected; patients with hs-CRP/SA ≥ 1.19 had a MACE incidence of 5.9 events per 100 patient-years, compared with 1.2 events per 100 patient-years in those with hs-CRP/AS < 1.19 (p < 0.001). Multivariate analysis confirmed that hs-CRP/SA ≥ 1.19 was associated with an approximately 6.5-fold increased risk of new MACEs (HR 6.513, 95% CI 3.928–10.797; p < 0.001). Conclusions: The hs-CRP/SA ratio is confirmed as a powerful prognostic marker in patients with CHF, associated with a significantly increased risk of MACEs.
- Open Access
- 26 February 2024
- Published by MDPI AG in Geriatrics
- Vol. 9 (2) , 28
Deprescribing in Older Poly-Treated Patients Affected with Dementia
Polypharmacy is an important issue in older patients affected by dementia because they are very vulnerable to the side effects of drugs’. Between October 2021 and September 2022, we randomly assessed 205 old-aged outpatients. The study was carried out in a Center for Dementia in collaboration with a university center. The primary outcomes were: (1) deprescribing inappropriate drugs through the Beers and STOPP&START criteria; (2) assessing duplicate drugs and the risk of iatrogenic damage due to drug–drug and drug–disease interactions. Overall, 69 men and 136 women (mean age 82.7 ± 7.4 years) were assessed. Of these, 91 patients were home care patients and 114 were outpatient. The average number of the drugs used in the sample was 9.4 drugs per patient; after the first visit and the consequent deprescribing process, the average dropped to 8.7 drugs per patient (p = 0.04). Overall, 74 potentially inappropriate drugs were used (36.1%). Of these, long half-life benzodiazepines (8.8%), non-steroidal anti-inflammatory drugs (3.4%), tricyclic antidepressants (3.4%), first-generation antihistamines (1.4%), anticholinergics (11.7%), antiplatelet drugs (i.e., ticlopidine) (1.4%), prokinetics in chronic use (1.4%), digoxin (>0.125 mg/day) (1.4%), antiarrhythmics (i.e., amiodarone) (0.97%), and α-blockers (1.9%) were included. The so-called “duplicate” drugs were overall 26 (12.7%). In total, ten potentially dangerous prescriptions were found for possible interactions (4.8%). We underline the importance of checking all the drugs taken periodically and discontinuing drugs with the lowest benefit-to-harm ratio and the lowest probability of adverse reactions due to withdrawal. Computer tools and adequately trained teams (doctors, nurses, and pharmacists) could identify, treat, and prevent possible drug interactions.
- 26 February 2024
- Published by MDPI AG in Geriatrics
- Vol. 9 (2) , 28
Open AccessDeprescribing in Older Poly-Treated Patients Affected with Dementia
Polypharmacy is an important issue in older patients affected by dementia because they are very vulnerable to the side effects of drugs’. Between October 2021 and September 2022, we randomly assessed 205 old-aged outpatients. The study was carried out in a Center for Dementia in collaboration with a university center. The primary outcomes were: (1) deprescribing inappropriate drugs through the Beers and STOPP&START criteria; (2) assessing duplicate drugs and the risk of iatrogenic damage due to drug–drug and drug–disease interactions. Overall, 69 men and 136 women (mean age 82.7 ± 7.4 years) were assessed. Of these, 91 patients were home care patients and 114 were outpatient. The average number of the drugs used in the sample was 9.4 drugs per patient; after the first visit and the consequent deprescribing process, the average dropped to 8.7 drugs per patient (p = 0.04). Overall, 74 potentially inappropriate drugs were used (36.1%). Of these, long half-life benzodiazepines (8.8%), non-steroidal anti-inflammatory drugs (3.4%), tricyclic antidepressants (3.4%), first-generation antihistamines (1.4%), anticholinergics (11.7%), antiplatelet drugs (i.e., ticlopidine) (1.4%), prokinetics in chronic use (1.4%), digoxin (>0.125 mg/day) (1.4%), antiarrhythmics (i.e., amiodarone) (0.97%), and α-blockers (1.9%) were included. The so-called “duplicate” drugs were overall 26 (12.7%). In total, ten potentially dangerous prescriptions were found for possible interactions (4.8%). We underline the importance of checking all the drugs taken periodically and discontinuing drugs with the lowest benefit-to-harm ratio and the lowest probability of adverse reactions due to withdrawal. Computer tools and adequately trained teams (doctors, nurses, and pharmacists) could identify, treat, and prevent possible drug interactions.
- Open Access
- 16 December 2023
- Published by MDPI AG in Geriatrics
- Vol. 8 (6) , 122
The Risk of Drug Interactions in Older Primary Care Patients after Hospital Discharge: The Role of Drug Reconciliation
Introduction: Drug–drug interactions (DDIs) represent an important clinical problem, particularly in older patients, due to polytherapy, comorbidity, and physiological changes in pharmacodynamic and pharmacokinetic pathways. In this study, we investigated the association between drugs prescribed after discharge from the hospital or clinic and the risk of DDIs with drugs used daily by each patient. Methods: We performed an observational, retrospective, multicenter study on the medical records of outpatients referred to general practitioners. DDIs were measured using the drug interaction probability scale. Potential drug interactions were evaluated by clinical pharmacologists (physicians) and neurologists. Collected data were analyzed using the Statistical Package for the Social Sciences. Results: During the study, we evaluated 1772 medical records. We recorded the development of DDIs in 10.3% of patients; 11.6% of these patients required hospitalization. Logistic regression showed an association among DDIs, sex, and the number of drugs used (p = 0.023). Conclusions: This observational real-life study shows that the risk of DDIs is common in older patients. Physicians must pay more attention after hospital discharge, evaluating the treatment to reduce the risk of DDIs.
- 16 December 2023
- Published by MDPI AG in Geriatrics
- Vol. 8 (6) , 122
Open AccessThe Risk of Drug Interactions in Older Primary Care Patients after Hospital Discharge: The Role of Drug Reconciliation
Introduction: Drug–drug interactions (DDIs) represent an important clinical problem, particularly in older patients, due to polytherapy, comorbidity, and physiological changes in pharmacodynamic and pharmacokinetic pathways. In this study, we investigated the association between drugs prescribed after discharge from the hospital or clinic and the risk of DDIs with drugs used daily by each patient. Methods: We performed an observational, retrospective, multicenter study on the medical records of outpatients referred to general practitioners. DDIs were measured using the drug interaction probability scale. Potential drug interactions were evaluated by clinical pharmacologists (physicians) and neurologists. Collected data were analyzed using the Statistical Package for the Social Sciences. Results: During the study, we evaluated 1772 medical records. We recorded the development of DDIs in 10.3% of patients; 11.6% of these patients required hospitalization. Logistic regression showed an association among DDIs, sex, and the number of drugs used (p = 0.023). Conclusions: This observational real-life study shows that the risk of DDIs is common in older patients. Physicians must pay more attention after hospital discharge, evaluating the treatment to reduce the risk of DDIs.
- Open Access
- 30 August 2023
- Published by MDPI AG in Preprints.org
The Risk of Drug Interactions in Older Primary Care Patients after Hospital Discharge; the Role of Drug Reconciliation
Introduction: Drug interactions (DDIs) represent an important clinical problem particularly in elderly patients due to polytherapy, comorbidity and physiological change in pharmacodynamic and pharmacokinetic pathways. In this study we investigated the association between drugs prescribed during hospital or clinical room discharge and the development of DDIs with drugs daily used from each patient. Methods: we performed an observational, retrospective, multicenter study on medical records of outpatients referred to general practitioners. Drug interactions (DDIs) were measured using the drug interactions probability scale. Collected data were analyzed using the Statistical Package for the Social Sciences. Results: During the study we evaluated 1,622 medical records. We recorded the development of DDIs in 10.3% of patients, of those 11.6% induced the hospitalization. Logistic regression showed an association between DDIs and sex and number of drugs used (P = 0.023). Conclusion: this real-life study shows that DDIs are common in elderly patients and physicians must take more attention after hospital discharge revaluating the treatment in order to reduce the risk of DDIs and hospitalization.
- 30 August 2023
- Published by MDPI AG in Preprints.org
Open AccessThe Risk of Drug Interactions in Older Primary Care Patients after Hospital Discharge; the Role of Drug Reconciliation
Introduction: Drug interactions (DDIs) represent an important clinical problem particularly in elderly patients due to polytherapy, comorbidity and physiological change in pharmacodynamic and pharmacokinetic pathways. In this study we investigated the association between drugs prescribed during hospital or clinical room discharge and the development of DDIs with drugs daily used from each patient. Methods: we performed an observational, retrospective, multicenter study on medical records of outpatients referred to general practitioners. Drug interactions (DDIs) were measured using the drug interactions probability scale. Collected data were analyzed using the Statistical Package for the Social Sciences. Results: During the study we evaluated 1,622 medical records. We recorded the development of DDIs in 10.3% of patients, of those 11.6% induced the hospitalization. Logistic regression showed an association between DDIs and sex and number of drugs used (P = 0.023). Conclusion: this real-life study shows that DDIs are common in elderly patients and physicians must take more attention after hospital discharge revaluating the treatment in order to reduce the risk of DDIs and hospitalization.